Skip to content
lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BridgeBio Pharma, Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
March 11, 2026
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
March 4, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 17, 2026
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
February 13, 2026
←
Previous Page
1
2
3
4